Given prior observations of ARG-1 production by TANs and ARG-1 blockade reducing tumour growth in an animal model of NSCLC, the authors suggested that tumours with highly frequent granulocytes in either tumour or stroma could be targeted with ARG-1-blocking therapy [75,76,77]. This evidence concerns the gene ARG1 and non-small cell lung carcinoma.